Clin Exp Rheumatol:血清微纤维相关蛋白4(MFAP4)水平升高与RA滑膜炎无关,但反映潜在心血管合并症

2019-12-23 xiangting MedSci原创

尽管进行了强化治疗,但MFAP4仍高于诊断时的基线水平,在RA早期或晚期均与滑膜炎无关。

这项研究旨在探讨类风湿性关节炎(RA)的血清MFAP4及其与临床表型的关系。

早期RAERA):纳入47例新诊断的初治RA患者。在强化滑膜炎抑制治疗的12个月期间,连续记录血清MFAP4临床和实验室疾病变量。长期RALRA):纳入317例接受DMARD治疗的患者。记录疾病活动性、自身抗体状态、关节外表现和心血管疾病的发病率。从13例未经治疗的ERA患者获得配对的血清和滑液样本。健康献血者作为参考点。通过AlphaLISA免疫测定进行MFAP4定量。使用单因素、多因素和混合效应回归模型进行统计分析。

ERA组:MFAP4从基线开始增加,在12个月随访时明显升高,为17.8 U/l [12.6;24.1],而健康对照组为12.7 U/l [9.5;15.6]p <0.001MFAP4与关节计数或C反应蛋白无关。LRA组:MFAP4升高,为25.9 U/l[20.4;33.7],而健康对照组为17.6U/l [13.7;21.2]p<0.0001,但与疾病活动性指标或关节外症状无关。值得注意的是,MFAP4与吸烟(p<0.0001)和抗环瓜氨酸肽抗体(抗CCP)呈负相关,p=0.005。与收缩压(p=0.001)和同时出现3个心血管事件和/或危险因素(p<0.0001)呈正相关。血清:滑膜液MFAP4比为21

尽管进行了强化治疗,但MFAP4仍高于诊断时的基线水平,在RA早期或晚期均与滑膜炎无关。相关性模式表明,MFAP4升高可能反映了RA相关血管的重塑。

原始出处:

S. Issa. Increased serum levels of microfibrillar-associated protein 4 (MFAP4) are not associated with clinical synovitis in rheumatoid arthritis but may reflect underlying cardiovascular comorbidity. Clin Exp Rheumatol. December 2019.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1825873, encodeId=ede918258e3e6, content=<a href='/topic/show?id=c52d388137b' target=_blank style='color:#2F92EE;'>#合并症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38813, encryptionId=c52d388137b, topicName=合并症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Tue Jun 02 01:27:00 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968672, encodeId=209c19686e264, content=<a href='/topic/show?id=bf70e24322' target=_blank style='color:#2F92EE;'>#FAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7243, encryptionId=bf70e24322, topicName=FAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Sun Nov 22 14:27:00 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379507, encodeId=cbc013e950790, content=<a href='/topic/show?id=09e46655974' target=_blank style='color:#2F92EE;'>#滑膜炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66559, encryptionId=09e46655974, topicName=滑膜炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a98f453, createdName=pcw106, createdTime=Wed Dec 25 02:27:00 CST 2019, time=2019-12-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1825873, encodeId=ede918258e3e6, content=<a href='/topic/show?id=c52d388137b' target=_blank style='color:#2F92EE;'>#合并症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38813, encryptionId=c52d388137b, topicName=合并症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Tue Jun 02 01:27:00 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968672, encodeId=209c19686e264, content=<a href='/topic/show?id=bf70e24322' target=_blank style='color:#2F92EE;'>#FAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7243, encryptionId=bf70e24322, topicName=FAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Sun Nov 22 14:27:00 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379507, encodeId=cbc013e950790, content=<a href='/topic/show?id=09e46655974' target=_blank style='color:#2F92EE;'>#滑膜炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66559, encryptionId=09e46655974, topicName=滑膜炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a98f453, createdName=pcw106, createdTime=Wed Dec 25 02:27:00 CST 2019, time=2019-12-25, status=1, ipAttribution=)]
    2020-11-22 mgqwxj
  3. [GetPortalCommentsPageByObjectIdResponse(id=1825873, encodeId=ede918258e3e6, content=<a href='/topic/show?id=c52d388137b' target=_blank style='color:#2F92EE;'>#合并症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38813, encryptionId=c52d388137b, topicName=合并症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Tue Jun 02 01:27:00 CST 2020, time=2020-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968672, encodeId=209c19686e264, content=<a href='/topic/show?id=bf70e24322' target=_blank style='color:#2F92EE;'>#FAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7243, encryptionId=bf70e24322, topicName=FAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Sun Nov 22 14:27:00 CST 2020, time=2020-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379507, encodeId=cbc013e950790, content=<a href='/topic/show?id=09e46655974' target=_blank style='color:#2F92EE;'>#滑膜炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66559, encryptionId=09e46655974, topicName=滑膜炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a98f453, createdName=pcw106, createdTime=Wed Dec 25 02:27:00 CST 2019, time=2019-12-25, status=1, ipAttribution=)]
    2019-12-25 pcw106

相关资讯

J Rheumatol:类风湿性关节炎vitD缺乏与疾病活动性、残疾和影像学进展的关联

在早期RA患者中,VitD缺乏与基线时更活跃和更严重的疾病相关,并可以预测1年内的残疾和影像学进展。

Sci Rep:类风湿性关节炎与健康对照手腕热成像特征的比较

这些创新性的发现提供了证据表明RA的基线热数据与健康个体存在明显差异。热成像有可能成为RA患者疾病活动性的辅助评估方法。

Semin Arthritis Rheu:间质性肺病类型对类风湿性关节炎死亡率的影响

这项研究通过系统的文献综述和荟萃分析发现,与其他RA-ILD类型相比,UIP类型与RA-ILD的死亡风险较高相关。

艾伯维的JAK抑制剂Rinvoq,获得欧盟批准治疗类风湿性关节炎

艾伯维(AbbVie)宣布,欧洲委员会(EC)已批准其JAK抑制剂Rinvoq(upadacitinib)用于治疗部分中度至重度活动性类风湿关节炎患者。

Arthritis Rheumatol:胰岛素抵抗通路与类风湿性关节炎的疾病活动性有关

这项研究旨在探讨胰岛素抵抗通路在类风湿性关节炎的炎症和疾病靶向治疗中的作用。 在一个爱尔兰RA队列中评估了RA疾病活动性和心血管危险因素,其中包括胰岛素抵抗和体重指数(BMI)。通过免疫组化评估RA和OA滑膜组织中的GLUT1和GLUT4活性。通过ELISA定量离体RA滑膜外植体促炎介质的自发释放和原发性滑膜成纤维细胞(RA SFC)细胞培养上清。蛋白印迹分析激活的AMPK(P‐AMPK)和GL

Semin Arthritis Rheu:血清球蛋白间隙升高是全身性风湿病血沉升高的可靠标志物

在球蛋白间隙升高的全身性风湿病患者亚组中,ESR总是升高的。